$1.37
-0.0099-0.72%
Pre-Market: Jul 19, 6:39 PM EDT
15 minutes delayed
Comments
Loading...
CytomX Therapeutics
CTMXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CytomX Therapeutics (NASDAQ:CTMX) Stock, Analyst Ratings, Price Targets, Forecasts
CytomX Therapeutics Inc has a consensus price target of $6.29 based on the ratings of 12 analysts. The high is $11 issued by HC Wainwright & Co. on December 22, 2021. The low is $2 issued by Mizuho on March 28, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, BMO Capital, and Wedbush on May 28, 2024, May 9, 2024, and May 9, 2024, respectively. With an average price target of $5.03 between Piper Sandler, BMO Capital, and Wedbush, there's an implied 267.13% upside for CytomX Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
BMO Capital
Wedbush
Jefferies
Mizuho
1calculated from analyst ratings
Analyst Ratings for CytomX Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor | — | Reiterates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 155.46% | Piper Sandler | Joseph Catanzaro | $2.25 → $3.5 | Upgrade | Neutral → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 162.02% | BMO Capital | Etzer Darout | $3.25 → $3.59 | Maintains | Market Perform | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 483.9% | Wedbush | Robert Driscoll | $3 → $8 | Upgrade | Neutral → Outperform | Get Alert |
| 05/06/2024 | Buy Now | 483.9% | Jefferies | Roger Song | $2.5 → $8 | Upgrade | Hold → Buy | Get Alert |
| 05/01/2024 | Buy Now | 137.21% | BMO Capital | Etzer Darout | → $3.25 | Reiterates | Market Perform → Market Perform | Get Alert |
| 04/22/2024 | Buy Now | — | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 137.21% | BMO Capital | Etzer Darout | $3.3 → $3.25 | Maintains | Market Perform | Get Alert |
| 03/12/2024 | Buy Now | 118.96% | Wedbush | Robert Driscoll | → $3 | Reiterates | Neutral → Neutral | Get Alert |
| 11/09/2023 | Buy Now | 118.96% | Wedbush | Robert Driscoll | $2 → $3 | Maintains | Neutral | Get Alert |
| 11/08/2023 | Buy Now | 118.96% | Wedbush | Robert Driscoll | $2 → $3 | Upgrade | Neutral → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 132.83% | BMO Capital | Etzer Darout | $3.15 → $3.19 | Maintains | Market Perform | Get Alert |
| 03/28/2023 | Buy Now | 45.97% | Mizuho | Mara Goldstein | $4 → $2 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 133.56% | BMO Capital | Etzer Darout | $2.6 → $3.2 | Maintains | Market Perform | Get Alert |
| 11/14/2022 | Buy Now | 89.77% | BMO Capital | Etzer Darout | $3 → $2.6 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/10/2022 | Buy Now | — | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Underweight | Get Alert |
| 07/11/2022 | Buy Now | — | Cowen & Co. | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/11/2022 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor | — | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 45.97% | Jefferies | Roger Song | $12 → $2 | Downgrade | Buy → Hold | Get Alert |
| 07/07/2022 | Buy Now | 118.96% | BMO Capital | Etzer Darout | $9 → $3 | Maintains | Outperform | Get Alert |
| 07/07/2022 | Buy Now | 483.9% | BTIG | Kaveri Pohlman | $16 → $8 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | 45.97% | Wedbush | Robert Driscoll | $6 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 155.46% | Barclays | Peter Lawson | $7 → $3.5 | Maintains | Overweight | Get Alert |
| 07/07/2022 | Buy Now | 191.95% | Mizuho | Mara Goldstein | $16 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 9.48% | Piper Sandler | Joseph Catanzaro | $10 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
| 06/24/2022 | Buy Now | 556.89% | BMO Capital | Etzer Darout | → $9 | Initiates | → Outperform | Get Alert |
| 03/02/2022 | Buy Now | 556.89% | JP Morgan | Gavin Scott | $10 → $9 | Maintains | Overweight | Get Alert |
| 01/18/2022 | Buy Now | 410.91% | Barclays | Peter Lawson | → $7 | Upgrade | Underweight → Overweight | Get Alert |
| 12/22/2021 | Buy Now | 702.86% | HC Wainwright & Co. | Robert Burns | $12 → $11 | Maintains | Buy | Get Alert |
| 11/15/2021 | Buy Now | 1067.8% | BTIG | Kaveri Pohlman | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for CytomX Therapeutics (CTMX) stock?
The latest price target for CytomX Therapeutics (NASDAQ:CTMX) was reported by HC Wainwright & Co. on June 27, 2024. The analyst firm set a price target for $0.00 expecting CTMX to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytomX Therapeutics (CTMX)?
The latest analyst rating for CytomX Therapeutics (NASDAQ:CTMX) was provided by HC Wainwright & Co., and CytomX Therapeutics reiterated their neutral rating.
When was the last upgrade for CytomX Therapeutics (CTMX)?
The last upgrade for CytomX Therapeutics Inc happened on May 28, 2024 when Piper Sandler raised their price target to $3.5. Piper Sandler previously had a neutral for CytomX Therapeutics Inc.
When was the last downgrade for CytomX Therapeutics (CTMX)?
The last downgrade for CytomX Therapeutics Inc happened on November 14, 2022 when BMO Capital changed their price target from $3 to $2.6 for CytomX Therapeutics Inc.
When is the next analyst rating going to be posted or updated for CytomX Therapeutics (CTMX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating CytomX Therapeutics (CTMX) correct?
While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a reiterated with a price target of $0.00 to $0.00. The current price CytomX Therapeutics (CTMX) is trading at is $1.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.